Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Michael Stocum, Walt Carney

Premium

On-Q-ity, a company developing diagnostics that analyze circulating tumor cells to guide treatment strategies for various cancers, announced that its board of directors has appointed Michael Stocum as president and CEO.

Stocum is president and founder of Personalized Medicine Partners, a firm that provides strategic advice to drug and diagnostic companies. Previously, at GlaxoSmithKline, Stocum led the biomarker business strategy for several cancer drugs.

Stocum's appointment comes after Mara Aspinall, founder and former CEO of Waltham, Mass.-based On-Q-ity, left the company last year to become president of Roche subsidiary Ventana Medical Systems.

In addition to Stocum's appointment, the board determined that Walt Carney, formerly On-Q-ity's chief scientific officer, will become the firm's scientific adviser.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.